Results for this period
Interim period (second quarter)1 October 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the Medical Support Business, growth in the number of projects driven by demand, expansion in the number of affiliated clinics and outsourced processing orders, service enhancements, improvements in operational efficiency and the development of new business partners contributed to results. In the D2C Business, the company restrained new customer acquisition, worked to increase cross-selling to existing customers and expand sales through marketplace channels, and reduced fixed costs through the introduction of AI bots.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥1,133,473 thousand (YoY +35.8%) |
| Operating profit | ¥138,170 thousand |
| Ordinary income | ¥134,535 thousand |
| Profit attributable to owners of the parent | ¥136,485 thousand |
| Net income per share | ¥38.63 |
| Equity ratio | End of the current fiscal period 65.6% / End of previous period 65.1% |
| Total assets | ¥3,397,952 thousand |
| Net assets | ¥2,243,499 thousand |
| Cash flows from operating activities | ¥162,953 thousand |
| Cash flows from investing activities | ¥-3,634 thousand |
| Cash flows from financing activities | ¥-92,354 thousand |
| Cash and cash equivalents at end of period | ¥1,369,266 thousand |
| Full-year earnings forecast | Net Sales ¥2,500 million (YoY +27.5%) / Operating profit ¥400 million (YoY +165.0%) / Ordinary income ¥390 million (YoY +155.9%) / Profit attributable to owners of the parent ¥250 million (YoY +467.0%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥2,500 million / Operating profit Not disclosed → ¥400 million / Ordinary income Not disclosed → ¥390 million / Profit attributable to owners of the parent Not disclosed → ¥250 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Medical Support Business ¥631,890 thousand (YoY +90.4%), D2C Business ¥376,022 thousand (YoY -25.2%), Other ¥125,560 thousand |
| Segment profit | Medical Support Business ¥88,122 thousand, D2C Business ¥162,838 thousand (YoY +13.4%), Other ¥95,318 thousand |
| Depreciation and amortization | ¥7,649 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 0 additions and 0 exclusions (no company names) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Held (対象者：Not disclosed) |
| Issued Shares at Period-End | 3,643,068 |
| Treasury Shares at Period-End | 100,023 |
| Factors Behind Changes in Business Performance | In the Medical Support Business, growth in the number of projects driven by demand, expansion in the number of affiliated clinics and outsourced processing orders, service enhancements, improvements in operational efficiency and the development of new business partners contributed to results. In the D2C Business, the company restrained new customer acquisition, worked to increase cross-selling to existing customers and expand sales through marketplace channels, and reduced fixed costs through the introduction of AI bots. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Medical Support Business, the number of projects, affiliated clinics and outsourced processing orders increased against a backdrop of demand. The company also advanced service enhancements, improvements in operational efficiency and the development of new business partners. In the D2C Business, the company restrained new customer acquisition, worked to increase cross-selling to existing customers and expand marketplace channels, and reduced fixed costs through the introduction of AI bots.